
DATROWAY® Plus Rilvegostomig Shows Tumor Response in Metastatic Urothelial Cancer Trial
DATROWAY® Plus Rilvegostomig Demonstrates Promising Tumor Responses in Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial Initial results from a sub-study of the ongoing TROPION-PanTumor03 phase 2 clinical trial have demonstrated encouraging efficacy of the combination of DATROWAY® (datopotamab deruxtecan)…












